CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
CureVac AG announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to CureVac on GMP-conforming pharmaceutical manufacturing methods for producing RNA, strengthening CureVac’s industry-leading position in GMP manufacturing of in vitro transcribed RNA.
CureVac is the first company in the mRNA field to receive a patent for the entire manufacturing process of in vitro transcribed RNA. The patent allowance covers processes for the in vitro transcription of template DNA including proprietary quality control steps for producing purified RNA.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, commented: “We are pleased to be the first mRNA company to be awarded this important Intellectual Property protecting our entire process for producing transcribed RNA material from template DNA. This new IP supports our leading position in GMP-conforming mRNA manufacturing. As early as 2006, – when we were the only business enterprise in the mRNA field – we established our first GMP facility to manufacture mRNA. Our highest priority has always been to create ultra-pure mRNA at lowest cost of goods. Based on our extensive know-how and IP, we are currently building our industrial-scale production facility designed to produce up to 30 million doses of RNA-based therapeutics per year.”
Other news from the department research and development
